RecruitingRecruiting
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
NCT02610413 · National Cancer Institute (NCI)
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
About this study
PRIMARY OBJECTIVES:
I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103).
OUTLINE:
Previously collected germline DNA samples are analyzed via whole exome sequencing.
Eligibility criteria
Inclusion Criteria:
* European American patients with deoxyribonucleic acid (DNA) available and designated case or control
* Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
* Patients who did not develop hypertension following a full course of treatment with bevacizumab
Study design
Enrollment target: 354 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2014-03-25
Estimated completion: 2100-01-01
Last updated: 2026-03-27
Interventions
Other: Laboratory Biomarker Analysis
Primary outcomes
- • Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension (Baseline)
Sponsor
National Cancer Institute (NCI) · nih
Contacts & investigators
InvestigatorBryan P Schneider · principal_investigator, Eastern Cooperative Oncology Group
All locations (1)
Eastern Cooperative Oncology GroupRecruiting
Boston, Massachusetts, United States